Prothena Announces Board of Directors Update

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that Paula Cobb will step down from Prothena's Board of Directors to join Manifold Bio as its Chief Operating Officer. During her six-year tenure, Ms. Cobb played a significant role in which she made key contributions to the Company's vision and strategy. “I would like to than.

Business Wire • Dec 12, 2025

Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

DUBLIN, Ireland--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025.

Business Wire • Nov 19, 2025

Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Phase 2 clinical data for coramitug, a potential first-in-class amyloid depleter antibody, for the treatment of ATTR-CM published in Circulation.

Business Wire • Nov 11, 2025

Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus

Prothena's Q3 loss widened as revenues fell short of estimates, but its Alzheimer and Parkinson's drug programs gained FDA momentum and key collaborations advanced.

Zacks Investment Research • Nov 7, 2025

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the third quarter and first nine months of 2025 and provided business highlights.

Business Wire • Nov 6, 2025

Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates

Prothena (PRTA) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $1.1 per share a year ago.

Zacks Investment Research • Nov 6, 2025

Prothena to Report Third Quarter 2025 Financial Results on November 6

DUBLIN, Ireland--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena will report its third quarter 2025 financial results on Thursday November 6, 2025, after the close of the U.S. financial markets.

Business Wire • Oct 30, 2025

Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--PRTA announced that BMS communicated that the FDA granted Fast Track Designation to BMS-986446, an anti-tau antibody in P2 for Alzheimer's disease.

Business Wire • Oct 1, 2025

Prothena Down 40% Year to Date: What Lies Ahead for the Stock?

Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.

Zacks Investment Research • Sep 11, 2025

Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue?

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 3, 2025